Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris(UPMC Hillman Cancer Center), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Jérôme Fayette(Centre Léon Bérard), J. Guigay(Centre Antoine Lacassagne), A. Dimitrios Colevas(Stanford University), Lisa Licitra(Fondazione IRCCS Istituto Nazionale dei Tumori), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Stefan Kasper(West German Heart and Vascular Center Essen), Everett E. Vokes(University of Chicago Medical Center), Caroline Even(Institut Gustave Roussy), Francis P. Worden(University of Michigan–Ann Arbor), Nabil F. Saba(Emory University), Lara Carmen Iglesias Docampo(Hospital Universitario 12 De Octubre), Robert I. Haddad(Dana-Farber/Harvard Cancer Center), Tamara Rordorf(University Hospital of Zurich), Naomi Kiyota(Kobe University Hospital), Makoto Tahara(National Cancer Center Hospital East), Mark Lynch(Bristol-Myers Squibb (United States)), Vijayvel Jayaprakash(Bristol-Myers Squibb (United States)), Li Li(Bristol-Myers Squibb (United States)), Maura L. Gillison(The University of Texas MD Anderson Cancer Center)
Cited by 797Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis